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Abstract
Background: The fact that prognoses remain poor in patients with advanced hepatocellular carcinoma highlights
the demand for suitable animal models to facilitate the development of anti-cancer medications. This study
employed a relatively non-invasive approach to establish an orthotopic hepatocellular carcinoma model in
immune-competent rats. This was done by ultrasound-guided implantation of cancer cells and the model was
used to evaluate the therapeutic efficacy of short-term and low-dose epirubicin chemotherapy.
Methods: Rat Novikoff hepatoma cells were injected percutaneously into the liver lobes of Sprague-Dawley rats
under the guidance of high resolution ultrasound. The implantation rate and the correlation between dissected
and ultrasound-measured tumor sizes were evaluated. A similar induction procedure was performed by means of
laparotomy in a different group of rats. Pairs of tumor measurement were compared by ultrasound and
computerized tomography scan. Rats with a successful establishment of the tumor were divided into the
treatment (7-day low-dose epirubicin) group and the control group. The tumor sizes were non-invasively
monitored by the same ultrasound machine. Blood and tumor tissues from tumor-bearing rats were examined by
biochemical and histological analysis respectively.
Results: Ultrasound-guided implantation of Novikoff hepatoma cells led to the formation of orthotopic
hepatocellular carcinoma in 60.4% (55/91) of the Sprague-Dawley rats. Moreover, tumor sizes measured by
ultrasound significantly correlated with those measured by calipers after sacrificing the animals (P < 0.00001). The
rate of tumor induction by ultrasound-guided implantation was comparable to that of laparotomy (55/91, 60.4% vs.
39/52, 75%) and no significant difference in sizes of tumor was noted between the two groups. There was a
significant correlation in tumor size measurement by ultrasound and computerized tomography scan. In tumor-
bearing rats, short-term and low-dose epirubicin chemotherapy caused a significant reduction in tumor growth,
and was found to be associated with enhanced apoptosis and attenuated proliferation as well as a decrease in the
microvessel density in tumors.
Conclusions: Ultrasound-guided implantation of Novikoff hepatoma cells is an effective means of establishing
orthotopic hepatocellular carcinoma in Sprague-Dawley rats. Short-term and low-dose epirubicin chemotherapy
had perturbed tumor progression by inducing apoptosis and neovascularization blockade.
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Hepatocellular carcinoma (HCC) is the most common
primary malignancy of the liver (70-85%). It is also one
of the most frequent malignancies worldwide, particu-
larly in Asia and Africa. The incidence is still rising in
some countries such as Central Europe, North America
and Oceania for unknown reasons [1]. Unfortunately,
most of the HCC patients have non-specific symptoms
[2] and will probably miss the chance of receiving
curative treatment. Ultrasound (with or without con-
trast agents) is sensitive in detecting small HCCs while
new generation computerized tomography (CT) with
spiral and triphasic scanners can improve the specifi-
city in differentiating HCC from other kinds of liver
tumors. Serum a-fetoprotein (AFP) is probably the
most frequently used tumor marker for the diagnosis
of HCC. However, the sensitivity and specificity of
AFP need further validation such as exploration of its
subtypes. Routine use of percutaneous needle biopsy of
HCC is controversial because of the risk of needle-
track seeding and is better reserved for situations
where definite histological diagnosis is mandatory
[3,4]. Although tumor resection and liver transplanta-
tion are currently the mainstays of curative therapies
for HCC, only 10-15% of newly diagnosed patients in
Asia have resectable tumors. Local therapies such as
radiofrequency ablation and alcohol injection are alter-
natives for small tumors and patients unsuitable for
surgical intervention with comparable success rates.
Transarterial chemoembolisation (TACE) is recom-
mended for selected cases of locally advanced large
unresectable tumors with good liver functional reserve
and no vascular involvement [5].
Since prognoses are dismal for advanced or metastatic
tumors [6], the development of a suitable model for
testing new treatment modalities for HCC is urgently
required. Screening of drug candidates for HCC is
usually performed using xenografted HCC in immune-
deficient mice such as nude or severe combined immu-
nodeficiency (SCID) mice. In such xenografted models,
tumors are relatively vulnerable because they are not
grown in vascularized livers. In addition, those studies
fail to delineate the efficacy of therapeutic agents in ani-
mals with intact immune systems. In order to develop
clinically applicable intervention strategies for HCC, it is
essential to create an immune-competent animal model
bearing orthotopic HCC.
To create animal models with orthotopic HCC, the
implantation of hepatoma cells through laparotomy
into syngeneic or immune-deficient animals have been
employed in previous studies [7,8]. However, it is
rather time-consuming and traumatic. Besides, the
experimental animals often suffer from adverse events
such as bleeding, infection, and tumor adhesion to the
tissues and organs. Conditions are even more compli-
cated when repeated monitoring of the tumor status
is needed. Percutaneous therapies such as radiofre-
quency ablation with the guidance of real-time Ultra-
sound (US) have been widely used for the treatment
of HCC with high efficacy and safety [9]. An US
machine can also be used as a tool for tumor implan-
tation and measuring the subsequent changes of the
created tumors [8]. However, due to the small size of
rat livers compared with those of humans, it is a pre-
requisite to have a high resolution US machine as
well as a high frequency probe for precise tumor mea-
surement and US-guided injection. In the current
study, therefore, we investigated the feasibility and
efficacy of creating orthotopic HCC (transplantable
liver cancer) in a rodent model by US-guided implan-
tation. We employed Novikoff hepatoma (N1-S1)
cells, which were derived from Sprague-Dawley (SD)
rats administered with N-2-fluorenylphthalamic acid
(FPA), for US-guided implantation into the liver lobes
of SD rats.
Epirubicin, which is similar to doxorubicin as a deriva-
tive of anthracycline, can inhibit topoiosomerase II-a
(TOP2A) enzyme through preventing the cleavage of
supercoiled DNA and blocking DNA transcription and
replication. It has been used both alone [10] and in
combination with other anticancer agents [11,12] in the
treatment of advanced HCC. Studies have shown that
regimens containing either epirubicin or doxorubicin
resulted in similar response rates and survival. However,
epirubicin caused less bone marrow suppression and
cardiotoxicity than doxorubicin [13]. Metronomic dos-
ing, a new concept of chemotherapy first described by
Browder et al., [14] and Klement et al., [15] is the use
of low-dose cytotoxic drugs, either by continuous infu-
sion or frequent administration without extended resting
periods in the treatment of malignancy. It is not as toxic
as the traditional maximum tolerated dose (MTD) of
chemotherapy and better accepted by patients. It also
has the additional benefit of targeting the tumor
endothelium instead of tumor cells resulting in an anti-
angiogenic effect [16].
In the current study, we first evaluated the feasibility
of using US-guided implantation of N1-S1 cells to gen-
erate orthotopic HCC in rats and the reliability of using
the same machine to monitor tumor progression within
the rats. Subsequently, rats bearing established HCC
were treated with short-term (7-day) and low-dose epir-
ubicin chemotherapy. We aimed at evaluating the thera-
peutic efficacy of this method and the related
mechanism underlying the treatment in this novel HCC
model.
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Cell cultures
Rat Novikoff hepatoma (N1-S1) cells were cultured in
the RPMI 1640 medium (Life Technologies, Rockville,
MD) containing 100 U/mL penicillin (Hyclone, Bio-
Check Laboratories Ltd., USA), 100 μg/mL streptomycin
(Hyclone, Bio-Check Laboratories Ltd., USA), 5% fetal
calf serum (GIBCO BRL, Rockville, MD) and 2 mmol/L
glutamine (Hyclone, Bio-Check Laboratories Ltd., USA)
under humidified conditions in 95% air and 5% CO2 at
37°C. A rat hepatocyte cell line (Clone-9) derived from
normal Sprague-Dawley rat liver was purchased from
Bioresource Collection and Research Center ( no. 60201;
Hsin-Chu, Taiwan).
Animal studies
All experimental procedures were reviewed and
approved by the Institutional Animal Care and Use
Committee before the study began, and we ensured that
all animals received humane care and that study proto-
cols complied with the institution’s guidelines (see Addi-
tional file 1). Male Sprague-Dawley (SD; 150 ± 50 g) rats
purchased from the National Animal Center (Taipei,
Taiwan) were used in this study. Guidelines for pain
experiments on conscious animals were adhered to
throughout the experiments. The animals were housed
two per cage, in [beta]-chip lined metal cages in
a central animal care facility with a 12-hour light and
12-hour dark cycle. They were fed with rat chow and
water ad libitum. After anesthetization, N1-S1 cells (5 ×
10
6 cells suspended in 100 μl of RPMI1640) were
injected percutaneously into the liver parenchyma of the
SD rats using a 29-gauge syringe under the guidance of
real-time US with a high frequency linear array transdu-
cer operating at 7-14 MHz (GE Logiq 9® Ultrasound
System). Similar induction procedure was performed by
means of laparotomy in a different group of rats.
Ten days after induction, the animals were anesthe-
tized and tumor sizes were measured by US in two per-
pendicular diameters and expressed as the mean of the
two measurements [8]. Subsequently, the rats were
sacrificed and the HCC sizes were measured by calipers.
Alternatively, tumor volume was estimated by the for-
mula: volume = (shortest diameter)
2 × (longest dia-
meter) × 0.5 [17]. Plasma samples were collected from
tumor-bearing rats and subjected to biochemical analy-
sis including glutamic oxaloacetic transaminase (GOT)
and glutamic pyruvic transaminase (GPT) activities
using an automatic biochemical analyzer (DAX96, Bayer
Corp. Diagnostic, Milan, Italy). Fifteen pairs of tumor
measurement were performed using US and functional
(perfusion) computerized tomography (CT) scan as pre-
viously described by Kan Z [18], while the results of
biochemical measurements were plotted and compared
by Pearson’s correlation.
Short-term (7-day) and low-dose epirubicin chemotherapy
for treatment of HCC in SD rats
After successful implantation of orthotopic HCC in the
10
th day, SD rats with comparable sizes of tumor were
equally divided into the treatment (n = 11) group and
the control (n = 11) group. Low-dose epirubicin at 0.3
mg/day/rat was injected through the tail vein in the
treatment group for seven days (the risk of congestive
heart failure might occur at cumulative doses greater
than 900 mg m
-2, about 300 mg kg
-1) [19,20]. After
completion of treatment, tumor sizes measured by US
were compared between groups and with those before
treatment. Moreover, actual tumor sizes were obtained
by caliper measurement after sacrificing the animals and
the tumors were also weighted. Peripheral blood was
drawn from the tail veins of the rats after completion of
treatment to check the white and red blood cells as well
as the platelet counts.
Western blot analysis
The protein extracts were isolated using RIPA buffer
(150 mM NaCl, 50 mM HEPES pH 7, 1% Triton X-100,
10% glycerol, 1.5 mM MgCl2, 1 mM EGTA) containing
a protease inhibitor (Roche Applied Science; Indianapo-
lis, IN). After separation in 12.5% SDS-PAGE, protein
samples were transferred onto polyvinylidene fluoride
(PVDF) membrane using blotting apparatus. The mem-
brane was blocked with 5% milk in TBS-T for 1 h.
Then, it was incubated with TOP2A antibody (1:500,
cell-signaling) for 1 h at room temperature. After incu-
bation with HRP-conjugated secondary antibody (1:5000
dilutions in 5% milk) for 60 minutes, the signals on
membrane were detected using ECL-plus luminol solu-
tion (Pharmacia; Piscataway, NJ) and exposed to X-ray
film for autoradiogram.
Immunohistochemical analysis
The paraffin-embedded tissue blocks were sectioned
into 3-millimeter slices and mounted on poly-L-lysine-
coated slides. After deparaffinization, the slides were
blocked with 3% hydrogen peroxide for 10 minutes and
subjected to antigen retrieval by microwave in 10 mM
citrate buffer for 15 minutes. TOP2A (1:50, cell-
signaling), Ki-67 antibodies (1:100 dilution, Dako, Den-
mark) and PECAM-1 (platelet endothelial cell adhesion
molecule-1, 1:50 dilution; Santa Cruz Biotechnology
Inc.) were applied onto the sections, which were then
incubated at room temperature for 60 minutes followed
by repeated washing with phosphate-buffered saline
(PBS). Horseradish peroxidase/Fab polymer conjugate
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applied to the sections and the sections were incubated
for 30 minutes. After rinsing with PBS, the sections
were incubated with peroxidase substrate diaminobenzi-
dine (1:20 dilution, Zymed) for 5 minutes. Thereafter,
the sections were counterstained with Gill’s hematoxylin
for 20 seconds, dehydrated with serial ethyl alcohol,
cleared with xylene, and finally mounted. For compari-
son, results of the percentage of Ki-67-positive staining
were counted under low power fields while PECAM-1
was presented as the amount of positive staining under
high power fields.
The terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) staining
The TUNEL assay was used to detect DNA fragmenta-
tion. Briefly, the hepatoma sections on slides were
deparaffinized, and then washed with PBS. TUNEL ana-
lysis was performed using the in situ Cell Death Detec-
tion Kit Fluorescein (Roche Molecular Biochemicals;
Indianapolis, IN) according to the manufacturer’s proto-
col. TUNEL-positive cells were visualized by immuno-
fluorescent microscopya n dc o u n t e du s i n ga2 0 ×
objective. TUNEL-positive cells containing FITC were
identified by co-localization with 4,6-diamidino-2-
phenylindole (DAPI) staining and by morphology. More
than 100 cells were counted for each variable per
experiment. The slides were viewed under a fluores-
cence microscope with green fluorescence set at
520 nm. The cells stained green indicated apoptotic
cells. For comparison, the amount of positive staining
was counted under low power fields.
Statistical analysis
The induction rate of HCC by the US-guided method
was presented as the percentage of rats with successful
tumor induction divided by the total number of rats
enrolled. The tumor sizes were expressed as mean ±
standard deviation. Pearson’s correlation was applied to
compare the results of US with the corresponding mea-
surements. Continuous variables were compared with
the Student’s t test. A P < 0.05 on two-tailed testing was
considered significant.
Results
Ultrasound-guided implantation of N1-S1 cells effectively
induced orthotopic HCC in SD rats
To generate orthotopic HCC in immune-competent
rats, N1-S1 cells were implanted into the liver lobes of
the anesthetized SD rats under the guidance of high
resolution US on day 1 (Figure 1a). After 10 days, US
revealed prominent HCC in 60.4% (55/91) of animals
with an average size of 16.23 mm (Figure 1b). The pre-
sence of HCC was further confirmed after sacrificing
animals for caliper measurement (Figure 1c). The rate of
tumor induction by US was comparable to that of lapar-
otomy (55/91, 60.4% vs. 39/52, 75%) and no significant
difference in the sizes of tumor was found between the
two groups (Number of rats: US vs. laparotomy: 55 vs.
39, P = 0.6759, Figure 1d). Indeed, it took much less
time to perform ultrasound implantation. Besides, the
animals recovered better and were free of adhesive
tumor nodules at injection sites. Therefore, ultrasound-
guided implantation of N1-S1 cells into liver lobes is an
effective means of inducing orthotopic HCC in SD rats.
The ultrasound-measured HCC size highly correlated with
the caliper measurement, plasma GOT level, and CT-
measured tumor size
To evaluate the accuracy of US measurement, we first
compared the US-measured HCC sizes with the caliper
measurement immediately after sacrificing the animals.
Arithmetic mean of tumor diameters were calculated
from width and length or alternatively, tumor volume
was estimated by the formula: volume = (shortest dia-
meter)
2 × (longest diameter) × 0.5. By using arithmetic
mean, the HCC sizes measured by US (16.23 ± 12.58
mm; n = 55) were similar to those of caliper measure-
ment (18.63 ± 12.95 mm; n = 55). Moreover, there was
an excellent correlation between US-measured and cali-
per-measured HCC sizes (Pearson’s correlation coeffi-
cient = 0.8697, n = 55, *** P < 0.0001, Figure 2a).
The biochemical parameters in blood samples from
HCC-bearing rats were determined to investigate the
relationship between US-measured HCC sizes and
plasma GOT/GPT levels. Interestingly, the US-measured
HCC sizes significantly correlated with plasma GOT level
(Pearson’s correlation coefficient = 0.6484, n = 71, *** P <
0.0001; Figure 2b), but not with GPT (data not shown).
As CT scan is a fast and reliable means for acquiring
two-dimensional tumor images, a portion of HCC-
bearing rats were subjected to CT scan examination
immediately after US diagnosis (Figure 2c). There was a
significant correlation in the tumor size measured (arith-
metic mean) by US and CT scan (Pearson’s correlation
coefficient = 0.687, n = 15, * P < 0.05; Figure 2d).
In addition, similar results were obtained by compar-
ing the tumor volumes (US vs. caliper: n = 55, correla-
tion coefficient= 0.7988, ***P < 0.0001; US vs. CT: n =
15, correlation coefficient= 0.9099, ***P < 0.0001). These
findings strongly supported the fidelity of US-based
monitoring of HCC progression in rats.
Short-term and low-dose epirubicin chemotherapy led to
stable disease in rats bearing established HCC
Subsequently, rats bearing established HCC were sub-
jected to short-term (7-day) and low-dose epirubicin ther-
apy to validate this animal model for drug screening
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day 10, the animals were divided into the treatment (7-day
low-dose epirubicin) group and the control group. After
completion of treatment, ultrasound monitoring revealed
that the tumor burden in the control group continued to
increase (**P < 0.01; Figure 3b), whereas the tumors in rats
treated with epirubicin showed no significant increment
(P = 0.1737; Figure 3b). After sacrificing the animals, it
was found that the tumor sizes of the control group were
significantly larger than those of the epirubicin group (* P
< 0.05; Figure 3c) while the tumor weights exhibited a
similar trend but showed no statistical significance (P =
0.0906; Figure 3d). On the other hand, epirubicin treat-
ment caused significant bone marrow suppression relative
to the control group in terms of pancytopenia (Figures 4a,
4b and 4c).
Short-term and low-dose epirubicin chemotherapy
induced apoptosis and neovascularization blockade in
HCC
Western blotting demonstrated abundant TOP2A
enzyme expressions in N1-S1 cells using protein extracts
from cancer cells and normal Clone 9 hepatocytes
(Figure 5a). Consistent results were also obtained from
immunohistochemical studies in tumor specimens (T:
tumor vs. N: non-tumor parts; Figures 5b, 5c and 5d).
To investigate the tumor-suppressing mechanism under-
lying epirubicin therapy, HCC samples were subjected to
various histological analyses. TUNEL staining revealed a
significant increase in the number of apoptotic cells in
epirubicin-treated tumors as compared with the control
group (Figure 6a). On the other hand, there was a sig-
nificant reduction of Ki67-positive proliferating cells in
the epirubicin-treated HCC (Figure 6b). Interestingly,
the number of PECAM-1-positive blood vessels was also
decreased in epirubicin-treated HCC (Figure 6c). There-
fore, short-term and low-dose epirubicin chemotherapy
had perturbed HCC proliferation through apoptosis
induction as well as angiogenesis inhibition. Moreover,
no significant correlation was obtained between the per-
fusion data (CT scan) and microvessel density changes
(Figure 6c).
Discussion
For the first time, the current study has demonstrated
the feasibility of ultrasound-guided implantation of
Figure 1 Ultrasound (US) -guided implantation of orthotopic HCC. (a) US-guided implantation on day 1. The needle track was shown on
the left of the picture (arrow). (b) US follow-up showing tumor growth on day 10. (c) The appearance of HCC after the sacrifice of rats. (d) No
significant difference in sizes of tumor formation with regard to the methods of induction by US and laparotomy were found (Number of rats:
US vs. laparotomy: 55 vs. 39, P = 0.6759).
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HCC in immune-competent rodent. Compared with
other HCC models including laparotomy, it possesses
the advantages of easy manipulation as it took less than
two hours to accomplish the implantation procedure in
twenty animals, minimal trauma to the experimental
animals, high reproducibility, early disease onset as
reflected in the early detection of tumor by US within
10 days after implantation, and the ability to evaluate
the effects of drug therapy on the tumors. Moreover,
the results of tumor measurement by US were consis-
tent with those assessed using functional CT scan and
the actual sizes measured after sacrificing the animals,
suggesting that US is an accurate and reliable means of
size assessment of the induced tumors.
There are limited chemotherapeutic options for treat-
ment of advanced HCC. Although the efficacies of many
chemotherapeutic agents have been tested in treating
HCC, the response rate is disappointing and ranges
between 10% and 15%. Besides, no survival advantage
has been demonstrated [21]. This may be due to the
unbearable side effects of the conventional maximum
tolerated dose (MTD) of chemotherapy upon patients
who already have chronic liver diseases and cirrhosis,
and the diversity in drug sensitivity due to genetic varia-
tions among the cancer cells [22]. In addition, tumor
organization further diminishes chemotherapeutic effi-
cacy through the development of multi-cellular drug
resistance [23]. On the other hand, the method of
metronomic chemotherapy is believed to attack the vas-
cular system of the tumor instead of tumor parenchyma
[14,15]. It has been demonstrated that this anti-
angiogenic property can facilitate the cytotoxic effects of
chemotherapeutic agents on the cancer cells [24-26].
This regimen can theoretically improve the tolerance of
patients and prolong the treatment period, thereby
enhancing the therapeutic efficacy of the cytotoxic drugs
on the tumor cells.
Evidence from both basal and clinical researches has
demonstrated the therapeutic effects of metronomic
Figure 2 Correlation of tumor sizes measured by ultrasound with various methods. (a) Correlation of tumor sizes measured by US and
calipers. (Pearson’s correlation coefficient = 0.8697, n = 55, *** P < 0.0001). (b) High correlation between tumor sizes (US) and GOT level
(Pearson’s correlation coefficient = 0.6484, n = 71, *** P < 0.0001) was noted. (c) Photographs of liver tumors measured by US and CT scan. (d)
High correlation of tumor measurements were obtained by US and CT scan (Pearson’s correlation coefficient = 0.687, n = 15, * P < 0.05).
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(7-day) and low-dose epirubicin for orthotopic HCC in the SD rats. (b) Mean tumor sizes before and after treatment in the control (n = 11) and
epirubicin (n = 11) groups showed significant increase in sizes in the control group (* P < 0.01), but not in the epirubicin group (P = 0.1737).
Besides, mean tumor size of the control group was significantly larger than that of the epirubicin group after the treatment (* P < 0.01) while
the sizes of tumors were similar before treatment (P = 0.5305). (c) Significant difference was seen in the mean dissected (real) tumor sizes
between the control and epirubicin groups after sacrifice (* P < 0.05). (d) No significant difference was noted in tumor weights between the
control and epirubicin groups after sacrifice. (P = 0.0906).
Figure 4 Bone marrow suppression resulting from short-term and low-dose epirubicin chemotherapy was expressed by differences in
peripheral blood cells between the two groups. (a) Differences in the WBC (** P < 0.01), (b) the RBC (* P < 0.01) and (c) the platelet
(* P < 0.05) counts between the treatment group (n = 11) and the control (n = 11) group.
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ovarian [27] and breast cancers. Colleoni et al. [28] have
shown in their clinical trial that low-dose metronomic
cyclophosphamide plus methotrexate is effective in the
treatment of metastatic breast cancer with cheaper cost
and prolonged tolerance to treatment. However, similar
reports on the treatment of HCC are rarely found in the
literature.
TOP2A over-expression seems to be correlating with
the aggressiveness of HCC in terms of early age onset,
advanced histological grading, microvascular invasion,
chemoresistence, tumor recurrence and mortality
[29,30]. These facts highlight the potential therapeutic
value of epirubicin in targeting TOP2A in the manage-
ment of HCC. Besides, epirubicin is one of the most fre-
quently used chemotherapeutic agents in the treatment
of HCC, either alone or in combination with other cyto-
toxic drugs, through various routes of administration
including TACE (transcatheter chemoembolization), sys-
temic chemotherapy, and trans-catheter arterial infusion
chemotherapy [31-37].
Although the present study is only a short-term inves-
tigation that fails to elucidate the long-term therapeutic
impact of epirubicin on HCC in an orthotopic animal
model, several findings are noteworthy. Firstly, we found
over-expression of TOP2A in N1-S1 HCC both in the
protein and the histology levels. Secondly, we found a
significant effect of the current regimen of epirubicin
chemotherapy on HCC growth in this brief animal trial
despite the association of bone marrow suppression.
Thirdly, the short-term and low-dose epirubicin had
high therapeutic potential in terms of histological
changes of HCC. It significantly suppressed the prolif-
eration of HCC cells as shown by the Ki-67 staining in
comparison with the control group. In addition, TUNEL
revealed an increase in the extent of apoptosis of HCC
after chemotherapy. Furthermore, and perhaps most
importantly, angiogenesis of the tumor endothelium
decreased in the treatment group. However, the optimal
dosages of metronomic chemotherapy, either chemopre-
ventive or therapeutic, remain elusive [38]. Moreover,
our orthotopic HCC animal model was not without
shortcomings such as a lack of concurrent chronic liver
diseases or cirrhosis that could not completely mimic
the clinical condition.
Furthermore, Tang et al., [39] had recently reported
an orthotopic advanced HCC model in which signifi-
cantly improved overall survival was observed using
Figure 5 Topoisomerase II-a (TOP2A) expression in N1-S1 HCC. (a) Protein extracts isolated from N1-S1 HCC cells and normal hepatocytes
(Clone 9) were subjected to the western blot analysis using TOP2A antibodies (1: 1000 dilution). As an internal control, the b-actin level was also
determined. (b) Nuclear and cytoplasm TOP2A expressions in tumor (T) and non-tumor (N) specimens from rat HCC were shown. Original
magnification ×100, the insets were then further magnified (×200) as shown in (c) tumor and (d) non-tumor parts.
Chan et al. BMC Gastroenterology 2010, 10:83
http://www.biomedcentral.com/1471-230X/10/83
Page 8 of 11various combinations of metronomic chemotherapy
regimens with targeted anti-angiogenic drugs. Through
implantation of tumor cells into the native liver
through laparotomy, they successfully created orthoto-
pic HCC in SCID mice. The size of the tumor was
then monitored by using a novel non-invasive
approach (transplantation of tumor cells that have
been transfected with the b-hCG gene). The results of
that study are impressive and encouraging. Both that
study and our present study have successfully estab-
lished valuable orthotopic HCC models that can be fol-
lowed noninvasively either using a gene transfection
method or sonographically. Our method has the addi-
tional advantage of being close to the clinical situation
in which ultrasound is the major tool for following
tumor progression. Also, both studies have demon-
strated the potential of low-dose chemotherapy, either
used alone or in combination with anti-angiogenic
agents, in the treatment of HCC.
Conclusions
In this study, encouraging result has been obtained by
the ultrasound-guided tumor implantation of N1-S1
cells that has led to the growth of orthotopic HCC in
about 60% of SD rats, which is comparable to the
method of laparotomy. It is a fairly effective and feasible
method for establishing an animal model of HCC for
future therapeutic trials. It greatly reduces the time per-
iod expected for the tumor response to the experimental
drugs. Moreover, we have shown the therapeutic effica-
cies of low-dose epirubicin on HCC growth in terms of
tumor size, cancer cell proliferation, apoptosis as well as
angiogenesis. On the other hand, the optimal dose of
metronomic epirubicin should be substantiated by
Figure 6 Histological changes of HCC after short-term and low-dose epirubicin chemotherapy, control (n = 6) vs. epirubicin (n = 6). (a)
Fluorescein-mediated TUNEL assay was performed to identify apoptotic nuclei (green), * P = 0.006. (b) Immunohistochemical staining of HCC by
Ki-67 (brown) was done for examining the effect of epirubicin on the cell proliferation of HCC, * P < 0.0063. (c) Effect of short-term and low-dose
epirubicin chemotherapy on tumor angiogenesis, arrows stand for the PECAM-1-positive blood vessels (* P = 0.0282).
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and running clinical trials in the future.
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